CM
EW icon

Crestline Management’s Edwards Lifesciences EW Stock Holding History

Crestline Management’s Portfolio EW Stock Details EW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-19,276
Closed -$1.27M – 768
2024
Q3 		$1.27M Buy
+19,276
New +$1.4M 0.07% 242
2022
Q1 		– Sell
-16,656
Closed -$2.16M – 279
2021
Q4 		$2.16M Sell
16,656
-8,427
-34% -$983K 0.16% 113
2021
Q3 		$2.84M Buy
+25,083
New +$2.86M 0.27% 83
2017
Q1 		– Sell
-58,341
Closed -$1.82M – 122
2016
Q4 		$1.82M Buy
+58,341
New +$1.89M 0.45% 10

Other funds holding EW

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM

Crestline Management's EW Position: Q4 2024 in Review

Crestline Management sold out of Edwards Lifesciences (EW) in Q4 2024, closing a stake of 19,276 shares — an estimated $1.27M sold.

Crestline Management first reported a position in EW in Q4 2016 and held it in 4 quarters. The position peaked at $2.84M in Q3 2021. 1,228 funds tracked by Wall St. Rank hold EW as of Q4 2024.

  • Crestline Management reported no remaining Edwards Lifesciences position as of Q4 2024 after selling out during the quarter.
  • Crestline Management sold 19,276 Edwards Lifesciences shares in Q4 2024, an estimated $1.27M.
  • Crestline Management first reported a position in Edwards Lifesciences in Q4 2016 and held it in 4 quarters.
  • Crestline Management's Edwards Lifesciences position peaked at $2.84M in Q3 2021.
  • 1,228 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q4 2024.

Based on Crestline Management's 13F filing for Q4 2024, filed 14 Feb 2025.